Clinical Scorecard: Top 10 evidence-based essentials in pulmonology

At a Glance

Key Highlights

• GINA and GOLD reports provide updated management strategies for asthma and COPD.
• Conditional recommendations for idiopathic pulmonary fibrosis treatment include transbronchial lung cryobiopsy.
• Dupilumab shows reduced exacerbations in COPD patients with high eosinophil counts.
• Updated ARDS guidelines recommend corticosteroids and ECMO for severe cases.
• Ensifentrine approved as maintenance therapy for COPD.

Guideline-Based Recommendations

Diagnosis

• Revised hemodynamic definitions and classification for pulmonary hypertension.
• Updated diagnostic algorithms for COPD and ARDS.

Management

• Conditional recommendations against antacid therapy for idiopathic pulmonary fibrosis.
• Use of neuromuscular blockers for early severe ARDS.

Monitoring & Follow-up

• BODE index for assessing mortality risk in COPD patients.

Risks

• Higher BODE index scores correlate with greater mortality risk.

Patient & Prescribing Data

Adults with moderate to severe COPD and asthma patients aged 12 years or older.

Dupilumab and mepolizumab reduce exacerbations in COPD; ensifentrine improves lung function.

Clinical Best Practices

• Implement updated vaccination recommendations for COPD management.
• Utilize evidence-based guidelines for the treatment of pulmonary hypertension.

Related Resources & Content

• Global Initiative for Asthma (GINA)
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)
• American Thoracic Society/European Respiratory Society/Japanese Respiratory Society Guidelines
• European Society of Cardiology/European Respiratory Society Guidelines
• FDA Approval of Ensifentrine